Second Opinion November 1, 2024
Christina Farr & Megan Wilson

That’s the question of the moment – and we explore it in-depth.

I co-wrote and researched this piece with health policy writer and former Politico journalist Megan Wilson.

Within the next decade, nearly half of Americans may qualify to take a GLP-1 drug like Ozempic or Wegovy — and, as demand rises, many employers are asking: How do we cover them?

As we all know, these medications aren’t cheap. Before drugmaker discounts, the price tag can be as much as $1,300 per dose. One study shows that GLP-1 drug costs become one of a company’s top five expenses once a plan begins covering them. Experts worry that even emerging generics will be too spendy for...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Employer, Patient / Consumer, Pharma / Biotech
Study: Why Quick Fixes Don’t Work in Workplace Wellness
How Can Employers Manage Rising Healthcare Costs in 2025?
Google maps the future of AI agents: Five lessons for businesses
The Two Events that Changed U.S. Healthcare for Everyone
How AI Can Transform Small Business M&A

Share This Article